Portfolio company Enterprise Therapeutics, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has closed a £4 million funding round, led by Innovations and Epidarex Capital.
The funds will be used to accelerate Enterprise's three drug discovery programmes. The company aims to treat chronic respiratory diseases, such as Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD), using novel muco-regulatory therapies. The potential new drugs would target mechanisms that increase the clearance of mucus or reduce levels of mucus production in order to alleviate the symptoms and complications associated with respiratory disease.
Dr Rob Woodman, Investor Director, Imperial Innovations commented: “Enterprise Therapeutics has made significant progress in the 18 months since Imperial Innovations first invested. We believe that the Company has the potential to become a leading player in respiratory disease.”